guest ::
| Home > Publications database > Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time. |
| Home > Publications database > Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time. |
| Journal Article | DKFZ-2022-00580 |
; ;
2022
Taylor & Francis Group
London [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1080/10428194.2022.2053529
Abstract: We examine changes in population level incidence and survival of patients diagnosed with myelodysplastic syndrome (MDS) in the United States in 2001-2016. Data were extracted from the Surveillance, Epidemiology, and End Results (SEER)-18 database. Period analysis was used to calculate one-, two-, and five-year survival. The incidence peaked at 5.6 per 100,000 in 2010 then decreased to 3.9 by 2016, with a decrease in the diagnoses of refractory anemia (RA) and RA with ringed sideroblasts (RARS) and a relative increase in RA with excess blasts (RAEB). Overall, one-, two-, and five-year relative survival decreased over time, going from 74.3%, 60.9%, and 42.3%, respectively, in 2008-2010 to 70.9%, 55.9%, and 37.6%, respectively, in 2014-2016. When survival was examined by histology, patients with RA/RARS and RAEB had similar survival expectations in 2008-2010 versus 2014-2016 and a decrease was observed for 5q-MDS. Our results highlight the need for new treatment options in MDS.
Keyword(s): Myelodysplastic syndromes ; incidence ; period analysis ; survival analysis
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
